Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MPN Advances Day 2019 | New therapies for MPNs: an update before ASH

Claire Harrison • 15 Nov 2019
MPN Advances Day 2019
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Bomedemstat Fedratinib Luspatercept Momelotinib Navitoclax Pacritinib Pelabresib Ropeginterferon alfa-2b Ruxolitinib
MAJIC

Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, highlights the range of new therapies for myeloproliferative neoplasms (MPNs) and what they can offer. This includes JAK, LSD1 and MDM2 inhibitors, among other strategies. This interview took place at the MPN Advances Day 2019 in London, UK.

More from Claire Harrison

Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF 2:06
Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF
Claire Harrison • 8 Dec 2025
Real-world data on the treatment of adolescents and young adults with MPNs 2:49
Real-world data on the treatment of adolescents and young adults with MPNs
Claire Harrison • 23 Jun 2025
Evolving strategies in MPNs: big data analysis, wearable devices, & targeted therapies 3:20
Evolving strategies in MPNs: big data analysis, wearable devices, & targeted therapies
Claire Harrison • 23 Jun 2025
72-week results from MANIFEST-2: pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis 2:17
72-week results from MANIFEST-2: pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis
Claire Harrison • 23 Jun 2025

Related Videos

Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US 2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat 2:12
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat
Prithviraj Bose • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals